Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study · References

References

CC BY 4.0 · NIHR Journals Library · approximately 20 min read

  1. Antony R, Daghem M, McCann GP, Daghem S, Moon J, Pennell DJ, et al. Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson 2011;13:57. 10.1186/1532-429X-13-5721978669
  2. El Aidi H, Adams A, Moons KG, Den Ruijter HM, Mali WP, Doevendans PA, et al. Cardiac magnetic resonance imaging findings and the risk of cardiovascular events in patients with recent myocardial infarction or suspected or known coronary artery disease: a systematic review of prognostic studies. J Am Coll Cardiol 2014;63:1031–45. 10.1016/j.jacc.2013.11.04824486280
  3. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2014;7:940–52. 10.1016/j.jcmg.2014.06.01225212800
  4. Pufulete M, Brierley RC, Bucciarelli-Ducci C, Greenwood JP, Dorman S, Anderson RA, et al. Formal consensus to identify clinically important changes in management resulting from the use of cardiovascular magnetic resonance (CMR) in patients who activate the primary percutaneous coronary intervention (PPCI) pathway. BMJ Open 2017;7:e014627. 10.1136/bmjopen-2016-014627
  5. National Institute for Cardiovascular Outcomes Research. Myocardial Ischaemia National Audit Project. URL: www.ucl.ac.uk/nicor/audits/minap/documents/annual_reports/minap-report-2013 (accessed 17 January 2019).
  6. Cardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, Roe MT, et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol 2009;103:766–71. 10.1016/j.amjcard.2008.11.03319268729
  7. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915–22. 10.1056/NEJM20000928343130311006367
  8. Lee JH, Park HS, Chae SC, Cho Y, Yang DH, Jeong MH, et al. Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry). Am J Cardiol 2009;104:182–9. 10.1016/j.amjcard.2009.03.01019576343
  9. Rasoul S, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Marcel Gosselink AT, et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009;20:415–21. 10.1097/MCA.0b013e32832e5c4c19641460
  10. Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes DR, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 2010;31:1701–7. 10.1093/eurheartj/ehq12920530505
  11. Vlaar PJ, Mahmoud KD, Holmes DR, van Valkenhoef G, Hillege HL, van der Horst IC, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011;58:692–703. 10.1016/j.jacc.2011.03.04621816304
  12. Lockie T, Ishida M, Perera D, Chiribiri A, De Silva K, Kozerke S, et al. High-resolution magnetic resonance myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant coronary stenoses as determined by fractional flow reserve. J Am Coll Cardiol 2011;57:70–5. 10.1016/j.jacc.2010.09.01921185504
  13. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, et al. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 2009;120:2207–13. 10.1161/CIRCULATIONAHA.109.87235819917885
  14. ClinicalTrials.gov. MR INFORM – MR Perfusion Imaging to Guide Management of Patients With Stable Coronary Artery Disease. URL: https://clinicaltrials.gov/ct2/show/NCT01236807 (accessed April 2018).
  15. Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson ML, APPROACH Investigators. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 2005;95:261–3. 10.1016/j.amjcard.2004.09.01415642564
  16. Meryon I, Patel N, Millane T, Varma C. Normal coronary angiography and primary percutaneous coronary intervention for ST elevation myocardial infarction: a literature review and audit findings. Int J Clin Pract 2010;64:1245–51. 10.1111/j.1742-1241.2010.02394.x20653800
  17. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest 2004;125:1877–84. 10.1378/chest.125.5.187715136402
  18. Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, Faraggi M, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol 2001;37:786–92. 10.1016/S0735-1097(00)01201-811693753
  19. Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A, et al. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005;45:19–24. 10.1016/j.jacc.2004.09.05615629367
  20. Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J 2007;28:1242–9. 10.1093/eurheartj/ehm11317478458
  21. Codreanu A, Djaballah W, Angioi M, Ethevenot G, Moulin F, Felblinger J, et al. Detection of myocarditis by contrast-enhanced MRI in patients presenting with acute coronary syndrome but no coronary stenosis. J Magn Reson Imaging 2007;25:957–64. 10.1002/jmri.2089717457796
  22. Laissy JP, Hyafil F, Feldman LJ, Juliard JM, Schouman-Claeys E, Steg PG, Faraggi M. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging. Radiology 2005;237:75–82. 10.1148/radiol.237104132216126925
  23. Leurent G, Langella B, Fougerou C, Lentz PA, Larralde A, Bedossa M, et al. Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries. Arch Cardiovasc Dis 2011;104:161–70. 10.1016/j.acvd.2011.01.00521497305
  24. Stensaeth KH, Fossum E, Hoffmann P, Mangschau A, Klow NE. Clinical characteristics and role of early cardiac magnetic resonance imaging in patients with suspected ST-elevation myocardial infarction and normal coronary arteries. Int J Cardiovasc Imaging 2011;27:355–65. 10.1007/s10554-010-9671-720652637
  25. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581–90. 10.1161/CIRCULATIONAHA.105.60650917015795
  26. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012;59:1604–15. 10.1016/j.jacc.2012.01.00722365425
  27. Brierley RC, Pufulete M, Harris J, Bucciarelli-Ducci C, Greenwood JP, Dorman S, et al. Developing a UK registry to investigate the role of cardiovascular magnetic resonance (CMR) in patients who activate the primary percutaneous coronary intervention (PPCI) pathway: a multicentre, feasibility study linking routinely collected electronic patient data. BMJ Open 2018;8:e018987. 10.1136/bmjopen-2017-018987
  28. Department of Health and Social Care. NHS Reference Costs. London: Department of Health and Social Care; 2014. URL: www.gov.uk/government/collections/nhs-reference-costs (accessed 27 October 2015).
  29. Welsh Government. Welsh Index of Multiple Deprivation. Cardiff: Welsh Government; 2011. URL: https://gov.wales/statistics-and-research/welsh-index-multiple-deprivation/?lang=en (accessed 16 January 2019).
  30. NHS Digital. Methodology to Create Provider and CIP Spells from HES APC Data. 2014. URL: http://content.digital.nhs.uk/media/11859/Provider-Spells-Methodology/pdf/Spells_Methodology.pdf (accessed 16 January 2019).
  31. International Statistical Classification of Diseases and Related Health. URL: https://icd.who.int/browse10/2016/en (accessed 20 December 2018).
  32. OPCS Classification of Interventions and Procedures version 4. URL: www.datadictionary.nhs.uk/web_site_content/supporting_information/clinical_coding/opcs_classification_of_interventions_and_procedures.asp (accessed 20 December 2018).
  33. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083–107. 10.1002/sim.369719757444
  34. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013.
  35. National Institute for Health and Care Excellence (NICE). The Pressure Wire Fractional Flow Reserve Measurement System for Coronary Artery Disease. London: NICE; 2014. URL: www.nice.org.uk/advice/mib2/chapter/technology-overview (accessed 16 January 2019).
  36. Stokes A, Doble B, Pufulete M, Reeves BC, Bucciarelli-Ducci C, Dorman S, et al. Cardiovascular magnetic resonance in emergency patients with multi-vessel disease or unobstructed coronary arteries: a cost-effectiveness analysis in the UK. BMJ Open 2019;9:e025700.
  37. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816–21. 10.1016/j.jacc.2009.11.09620579537
  38. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med 2017;376:1234–44. 10.1056/NEJMoa170106728317428
  39. Gurunathan S, Young G, Parsons G, Karogiannis N, Vamvakidou A, Elghamaz A, et al. 132 diagnostic accuracy of stress echocardiography compared with invasive coronary angiography with fractional flow reserve for the diagnosis of haemodynamically significant CAD in patients with known or suspected CAD. Heart 2016;102:A94–5. 10.1136/heartjnl-2016-309890.132
  40. Department of Health and Social Care. NHS Reference Costs 2015 to 2016. London: Department of Health and Social Care; 2016.
  41. Joint Formulary Committee. British National Formulary. 73 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2017.
  42. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services Research Unit, University of Kent; 2016.
  43. Hawe E, Cockcroft L. OHE Guide to UK Health and Health Care Statistics. London: Office of Health Economics; 2013.
  44. Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess 2011;15(31). 10.3310/hta15310
  45. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006;10(44). 10.3310/hta10440
  46. Tufts Medical Center. Cost-effectiveness Analysis (CEA) Registry. URL: http://healtheconomics.tuftsmedicalcenter.org/cear4/Home.aspx (accessed 6 April 2017).
  47. Aasa M, Henriksson M, Dellborg M, Grip L, Herlitz J, Levin LA, et al. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction: results of the Swedish Early Decision reperfusion Study (SWEDES) trial. Am Heart J 2010;160:322–8. 10.1016/j.ahj.2010.05.00820691839
  48. Nam J, Briggs A, Layland J, Oldroyd KG, Curzen N, Sood A, et al. Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed-trial and model-based methods. Cost Eff Resour Alloc 2015;13:19. 10.1186/s12962-015-0045-926578850
  49. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol 2005;100:229–40. 10.1016/j.ijcard.2004.08.04215823630
  50. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation 2015;131:861–70. 10.1161/CIRCULATIONAHA.114.01120125587100
  51. Kang WY, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, et al. Are patients with angiographically near-normal coronary arteries who present as acute myocardial infarction actually safe? Int J Cardiol 2011;146:207–12. 10.1016/j.ijcard.2009.07.00119664828
  52. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan AD, et al. Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 2016;17:1146–52. 10.1093/ehjci/jev28926590396
  53. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld A, Gard A, Jernberg T. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease. Circulation 2017;135:1481–9. 10.1161/CIRCULATIONAHA.116.02633628179398
  54. Dastidar AG, Rodrigues JC, Johnson TW, De Garate E, Singhal P, Baritussio A, et al. Myocardial infarction with nonobstructed coronary arteries: impact of CMR early after presentation. JACC Cardiovasc Imaging 2017;10:1204–6 10.1016/j.jcmg.2016.11.01028109935
  55. Dastidar AG, Rodrigues JC, Baritussio A, Bucciarelli-Ducci C. MRI in the assessment of ischaemic heart disease. Heart 2016;102:239–52. 10.1136/heartjnl-2014-30696326719357
  56. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, et al. Myocarditis or ‘true’ infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: a meta-analysis of individual patient data. Atherosclerosis 2015;241:87–91. 10.1016/j.atherosclerosis.2015.04.81625967935
  57. Wang ZJ, Zhang LL, Elmariah S, Han HY, Zhou YJ. Prevalence and prognosis of nonobstructive coronary artery disease in patients undergoing coronary angiography or coronary computed tomography angiography: a meta-analysis. Mayo Clin Proc 2017;92:329–46. 10.1016/j.mayocp.2016.11.01628259226
  58. Chopard R, Jehl J, Dutheil J, Genon VD, Seronde MF, Kastler B, et al. Evolution of acute coronary syndrome with normal coronary arteries and normal cardiac magnetic resonance imaging. Arch Cardiovasc Dis 2011;104:509–17. 10.1016/j.acvd.2011.05.00422044703
  59. Gerbaud E, Harcaut E, Coste P, Erickson M, Lederlin M, Labèque JN, et al. Cardiac magnetic resonance imaging for the diagnosis of patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Int J Cardiovasc Imaging 2012;28:783–94. 10.1007/s10554-011-9879-121538065
  60. Heijenbrok-Kal MH, Fleischmann KE, Hunink MG. Stress echocardiography, stress single-photon-emission computed tomography and electron beam computed tomography for the assessment of coronary artery disease: a meta-analysis of diagnostic performance. Am Heart J 2007;154:415–23.17719283
  61. Bettencourt-Silva J, De La Iglesia B, Donell S, Rayward-Smith V. On creating a patient-centric database from multiple Hospital Information Systems. Methods Inf Med 2012;51:210–20. 10.3414/ME10-01-006921818520
  62. García Álvarez L, Aylin P, Tian J, King C, Catchpole M, Hassall S, et al. Data linkage between existing health-care databases to support hospital epidemiology. J Hosp Infect 2011;79:231–5. 10.1016/j.jhin.2011.06.01621868128
  63. Torres V, Cerda M, Knaup P, Löpprich M. Assessment of automatically exported clinical data from a Hospital Information System for clinical research in multiple myeloma. Stud Health Technol Inform 2016;228:332–6.27577398
  64. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, ISPOR-SMDM Modeling Good Research Practices Task Force. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force – 2. Value Health 2012;15:804–11. 10.1016/j.jval.2012.06.01622999129
  65. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. New York, NY: Lawrence Erlbaum Associates, Publishers; 1988.
  66. Rycroft-Malone J. Formal consensus: the development of a national clinical guideline. Qual Health Care 2001;10:238–44. 10.1136/qhc.010023811743153
  67. Tukey JW. Exploratory Data Analysis. Reading, MA: Addison–Wesley; 1977.
  68. Pufulete M, Harris J, Dorman S, Cook L, Bucciarelli-Ducci C, Greenwood JP, et al. Feasibility of identifying important changes in care management resulting from cardiovascular magnetic resonance (CMR) using Hospital Episode Statistics data. BMC Med Res Methodol 2019; in press.
  69. Choudry FA, Weerackody RP, Timmis AD, Wragg A, Mathur A, Sporton S, et al. Importance of primary percutaneous coronary intervention for reducing mortality in ST-elevation myocardial infarction complicated by out-of-hospital cardiac arrest. Eur Heart J Acute Cardiovasc Care 2015;4:378–85. 10.1177/204887261455599025326470
  70. Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in the primary PCI era: a systematic review and meta-analysis. Int J Cardiol 2016;221:554–9. 10.1016/j.ijcard.2016.07.06927424314
  71. Corpus RA, House JA, Marso SP, Grantham JA, Huber KC, Laster SB, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J 2004;148:493–500. 10.1016/j.ahj.2004.03.05115389238
  72. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging 2014;7:930–9. 10.1016/j.jcmg.2014.05.01025212799
  73. NHS Health Research Authority. Confidentiality Advisory Group. 2018. URL: www.hra.nhs.uk/about-the-hra/our-committees/section-251/ (accessed 16 January 2019).
  74. National Joint Registry. Patient Consent. 2017. URL: www.njrcentre.org.uk/njrcentre/Healthcareproviders/Collectingdata/Patientconsent/tabid/101/Default.aspx (accessed 16 January 2019).
  75. Inflammatory Bowel Disease (IBD) Registry. Consent and Patient Information Materials. 2018. URL: http://ibdregistry.org.uk/consent-materials/ (accessed 16 January 2019).
  76. Great Britain. National Health Service Act 2006. London: The Stationery Office; 2006.
  77. NHS Digital. Obtaining-consent-for-patient-identifiable-and-or-sensitive-data-V2-050613/pdf/obtaining_consent_for_patient_identifiable_and_or_sensitive_data_V2_050613.pdf (accessed April 2018).
  78. Ipsos Mori. Public Support for Research in the NHS. 2011. URL: www.ipsos-mori.com/researchpublications/researcharchive/2811/Public-support-for-research-in-the-NHS.aspx (accessed 16 January 2019).
  79. Campbell B, Thomson H, Slater J, Coward C, Wyatt K, Sweeney K. Extracting information from hospital records: what patients think about consent. Qual Saf Health Care 2007;16:404–8. 10.1136/qshc.2006.02031318055882
  80. Kass NE, Natowicz MR, Hull SC, Faden RR, Plantinga L, Gostin LO, Slutsman J. The use of medical records in research: what do patients want? J Law Med Ethics 2003;31:429–33. 10.1111/j.1748-720X.2003.tb00105.x14626550
  81. Xafis V. The acceptability of conducting data linkage research without obtaining consent: lay people’s views and justifications. BMC Med Ethics 2015;16:79. 10.1186/s12910-015-0070-426577591
  82. Simon SR, Evans JS, Benjamin A, Delano D, Bates DW. Patients’ attitudes toward electronic health information exchange: qualitative study. J Med Internet Res 2009;11:e30. 10.2196/jmir.116419674960
  83. NHS England. NHS England Sets Out the Next Steps of Public Awareness About Care.Data. 2013. URL: www.england.nhs.uk/ourwork/tsd/care-data/ (accessed 16 January 2019).
  84. Goldacre B. The NHS plan to share our medical data can save lives – but must be done right. The Guardian, 21 February 2014. URL: www.theguardian.com/society/2014/feb/21/nhs-plan-share-medical-data-save-lives (accessed 16 January 2019).
  85. Williams H, Spencer K, Sanders C, Lund D, Whitley EA, Kaye J, Dixon WG. Dynamic consent: a possible solution to improve patient confidence and trust in how electronic patient records are used in medical research. JMIR Med Inform 2015;3:e3. 10.2196/medinform.352525586934
  86. Laurie G, Ainsworth J, Cunningham J, Dobbs C, Jones KH, Kalra D, et al. On moving targets and magic bullets: can the UK lead the way with responsible data linkage for health research? Int J Med Inform 2015;84:933–40. 10.1016/j.ijmedinf.2015.08.01126342668
  87. HM Government, NHS, National Information Board. Personalised Health and Care 2020. 2014. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/384650/NIB_Report.pdf (accessed 16 January 2019).
  88. Justinia T. The UK’s National Programme for IT: why was it dismantled? Health Serv Manage Res 2017;30:2–9. 10.1177/095148481666249228166675
  89. Gliklich RE, Dreyer NA, Leavy MB, editors. Chapter 15: Interfacing Registries With Electronic Health Records. In Registries for Evaluating Patient Outcomes: A User’s Guide [Internet]. 3rd edition. Rockville, MD: Agency for Healthcare Research and Quality (US); 2014.
  90. Ludman PF. BCIS Audit Returns Adult Interventional Procedures Jan 2014 to Dec 2014. 2015. URL: www.bcis.org.uk/wp-content/uploads/2017/01/BCIS-audit-2014.pdf (accessed 16 January 2019).
  91. NHS England. Diagnostic Imaging Dataset. URL: www.england.nhs.uk/statistics/statistical-work-areas/diagnostic-imaging-dataset/ (accessed 16 January 2019).
  92. Royal College of Surgeons. URL: www.rcseng.ac.uk/search/#SearchTerm=pre-operative (accessed February 2019).
  93. Dastidar AG, Ahmed A, McAlindon E, Lawton C, Manghat N, Hamilton M, et al. Incremental value of cardiovascular magnetic resonance imaging in patients surviving non-traumatic out-of-hospital cardiac arrest: a tertiary UK centre experience. Heart 2014;100:A79–80. 10.1136/heartjnl-2014-306118.134
  94. Monney PA, Sekhri N, Burchell T, Knight C, Davies C, Deaner A, et al. Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. Heart 2011;97:1312–18. 10.1136/hrt.2010.20481821106555
  95. Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. cardiac magnetic resonance imaging for the diagnosis of left ventricular thrombus: a systematic review. Can J Cardiol 2015;31:785–91. 10.1016/j.cjca.2015.01.01125913472
  96. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007;28:1709–16. 10.1093/eurheartj/ehm18417556348
  97. Ruggieri A, Piraino D, Dendramis G, Cortese B, Carella M, Buccheri D, et al. STEMI patients and nonculprit lesions: to treat or not to treat? And when? A review of most recent literature. Catheter Cardiovasc Interv 2015;87:1258–68 10.1002/ccd.2623626367867
  98. El-Hayek GE, Gershlick AH, Hong MK, Casso Dominguez A, Banning A, Afshar AE, et al. Meta-analysis of randomized controlled trials comparing multivessel versus culprit-only revascularization for patients with ST-segment elevation myocardial infarction and multivessel disease undergoing primary percutaneous coronary intervention. Am J Cardiol 2015;115:1481–6. 10.1016/j.amjcard.2015.02.04625840579
  99. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78–140. 10.1016/j.jacc.2012.11.01923256914
  100. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–619. 10.1093/eurheartj/ehs21522922416
  101. Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
  102. Kafka F. Metamorphosis, and other stories. Translated by Willa and Edwin Muir. London: Penguin Modern Classics; no. 1572; 1961.
  103. Emrich T, Emrich K, Abegunewardene N, Oberholzer K, Dueber C, Muenzel T, Kreitner KF. Cardiac MR enables diagnosis in 90% of patients with acute chest pain, elevated biomarkers and unobstructed coronary arteries. Br J Radiol 2015;88:20150025. 10.1259/bjr.2015002525782462
  104. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. A Cost-effectiveness Model Comparing Alternative Management Strategies for the Use of Glycoprotein IIbIIIa Antagonists in Non-ST-Elevation Acute Coronary Syndrome. Report to the National Institute for Clinical Excellence. London: National Institute of Health and Care Excellence; 2002.
  105. Daniel M, Agewall S, Caidahl K, Collste O, Ekenbäck C, Frick M, et al. Effect of myocardial infarction with nonobstructive coronary arteries on physical capacity and quality of life. Am J Cardiol 2017;120:341–6. 10.1016/j.amjcard.2017.05.00128610801
  106. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011;41:95–105. 10.1016/j.semarthrit.2010.12.00121420149
  107. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, Marteau T. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998;2(3).
  108. Hutchings A, Raine R. A systematic review of factors affecting the judgments produced by formal consensus development methods in health care. J Health Serv Res Policy 2006;11:172–9. 10.1258/13558190677764165916824265
  109. Regulation (EU) 2016/679 of the European Parliament and of the Council. URL: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32016R0679&from=EN (accessed January 2019).
  110. European Commission. Data Protection. URL: https://ec.europa.eu/info/law/law-topic/data-protection_en (accessed January 2019).
  111. NHS Digital. Data Access Request Service (DARS). URL: https://digital.nhs.uk/services/data-access-request-service-dars (accessed 16 January 2019).
  112. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59:1799–808. 10.1016/j.jacc.2012.01.03722575319
  113. Eitel I, Desch S, de Waha S, Fuernau G, Gutberlet M, Schuler G, Thiele H. Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 2011;97:2038–45. 10.1136/heartjnl-2011-30009821990384
  114. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010;55:2470–9. 10.1016/j.jacc.2010.01.04920510214
  115. Klug G, Mayr A, Schenk S, Esterhammer R, Schocke M, Nocker M, et al. Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:46. 10.1186/1532-429X-14-4622788728
  116. Wong TC, Piehler K, Puntil KS, Moguillansky D, Meier CG, Lacomis JM, et al. Effectiveness of late gadolinium enhancement to improve outcomes prediction in patients referred for cardiovascular magnetic resonance after echocardiography. J Cardiovasc Magn Reson 2013;15:6. 10.1186/1532-429X-15-623324403
  117. Parsai C, O’Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012;14:54. 10.1186/1532-429x-14-5422857649
  118. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012;5:370–7. 10.1016/j.jcmg.2011.11.02122498326
  119. Artis NJ, Thomson J, Plein S, Greenwood JP. Percutaneous closure of postinfarction ventricular septal defect: cardiac magnetic resonance-guided case selection and postprocedure evaluation. Can J Cardiol 2011;27:869.e3–5. 10.1016/j.cjca.2011.01.018
  120. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760–5. 10.1161/01.CIR.0000150390.04704.B715583079
  121. Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalani A, Dorian P, et al. Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. J Cardiovasc Magn Reson 2012;14:69. 10.1186/1532-429X-14-6923043729
  122. Alexandre J, Saloux E, Dugué AE, Lebon A, Lemaitre A, Roule V, et al. Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long-term appropriate ICD therapy in patients with coronary artery disease. J Cardiovasc Magn Reson 2013;15:12. 10.1186/1532-429X-15-1223331500
  123. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011;13:29. 10.1186/1532-429x-13-2921668964
  124. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002;39:194–201. 10.1016/S0735-1097(01)01747-811788207
  125. Bilchick KC, Dimaano V, Wu KC, Helm RH, Weiss RG, Lima JA, et al. Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging 2008;1:561–8. 10.1016/j.jcmg.2008.04.01319356481
  126. Ellims AH, Pfluger H, Elsik M, Butler MJ, Hare JL, Taylor AJ. Utility of cardiac magnetic resonance imaging, echocardiography and electrocardiography for the prediction of clinical response and long-term survival following cardiac resynchronisation therapy. Int J Cardiovasc Imaging 2013;29:1303–11. 10.1007/s10554-013-0215-923568562
  127. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 2007;153:105–12. 10.1016/j.ahj.2006.10.01517174647
  128. White JA, Yee R, Yuan X, Krahn A, Skanes A, Parker M, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2006;48:1953–60. 10.1016/j.jacc.2006.07.04617112984
  129. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M. Prognostic value of stress cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62:826–38. 10.1016/j.jacc.2013.03.08023727209
  130. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012;379:453–60. 10.1016/S0140-6736(11)61335-422196944
  131. Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle K, et al. Superior diagnostic performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: the secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial). J Cardiovasc Magn Reson 2012;14:61. 10.1186/1532-429X-14-6122938651
  132. Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation 1999;99:763–70. 10.1161/01.CIR.99.6.7639989961
  133. Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart 2012;98:1743–9. 10.1136/heartjnl-2012-30196223151669
  134. Weinsaft JW, Kim RJ, Ross M, Krauser D, Manoushagian S, LaBounty TM, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging 2009;2:969–79. 10.1016/j.jcmg.2009.03.01719679285
  135. Srichai MB, Junor C, Rodriguez LL, Stillman AE, Grimm RA, Lieber ML, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J 2006;152:75–84. 10.1016/j.ahj.2005.08.02116824834
  136. Wong DT, Leung MC, Das R, Liew GY, Williams K, Dundon BK, et al. Diagnostic accuracy of adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial infarction post primary angioplasty. J Cardiovasc Magn Reson 2011;13:62. 10.1186/1532-429X-13-6222017888
  137. Doesch C, Seeger A, Doering J, Herdeg C, Burgstahler C, Claussen CD, et al. Risk stratification by adenosine stress cardiac magnetic resonance in patients with coronary artery stenoses of intermediate angiographic severity. JACC Cardiovasc Imaging 2009;2:424–33. 10.1016/j.jcmg.2008.11.01719580724
  138. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;121:2462–508. 10.1161/CIR.0b013e3181d44a8f20479157
  139. Hoffmann U, Globits S, Schima W, Loewe C, Puig S, Oberhuber G, Frank H. Usefulness of magnetic resonance imaging of cardiac and paracardiac masses. Am J Cardiol 2003;92:890–5. 10.1016/S0002-9149(03)00911-114516903
  140. Chan PG, Smith MP, Hauser TH, Yeon SB, Appelbaum E, Rofsky NM, Manning WJ. Noncardiac pathology on clinical cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 2009;2:980–6. 10.1016/j.jcmg.2009.04.01419679286
  141. McKenna DA, Laxpati M, Colletti PM. The prevalence of incidental findings at cardiac MRI. Open Cardiovasc Med J 2008;2:20–5. 10.2174/187419240080201002018949093
  142. Wyttenbach R, Médioni N, Santini P, Vock P, Szucs-Farkas Z. Extracardiac findings detected by cardiac magnetic resonance imaging. Eur Radiol 2012;22:1295–302. 10.1007/s00330-011-2369-y22215074
← ConclusionAcknowledgements →

Attribution. Jessica M Harris; Rachel C Brierley; Maria Pufulete; Chiara Bucciarelli-Ducci; Elizabeth A Stokes; John P Greenwood et al. (2019). A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK544461. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support